Responses
Clinical/translational cancer immunotherapy
Original research
Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potential
Compose a Response to This Article
Other responses
No responses have been published for this article.
